HomeNewsGlobal Pharma

PhotonPharma Welcomes Derek Brown as its New CEO

PhotonPharma Welcomes Derek Brown as its New CEO

PhotonPharma has announced the appointment of Derek Brown as its new Chief Executive Officer.

With more than 25 years of diverse biopharmaceutical experience across the entire product lifecycle, Derek brings a wealth of strategic, operational, and financial expertise to guide PhotonPharma through its next phase of growth.

Brown replaces Alan Rudolph who will step down after leading the company to a successful FDA clearance and will remain on the Board of Directors. 

Before joining PhotonPharma, Derek served as the Global Commercial Development Lead at Rallybio, where he developed the company's commercial vision, capabilities, and operational plans. He was instrumental in conveying these plans to investors and business development partners, setting a strong foundation for the company's future commercial success.

Derek's extensive experience includes leadership roles at Chiasma, where he helped prepare the company for its first commercial launch and played a key role in its successful sale to Amryt Pharma. At Alexion Pharmaceuticals, Derek led a global team responsible for the commercialization of Ultomiris and marketing efforts for Soliris. His leadership in launching products, new product planning, and market access was further honed during his 12 years at Boehringer Ingelheim in both the US and Germany.

Derek holds a BA in Cellular Structure and Function and in Economics from Middlebury College, and an MBA from The Tuck School of Business at Dartmouth College. His unique blend of scientific understanding and business acumen will be critical in driving PhotonPharma's continued innovation and growth.

"Derek's leadership and deep understanding of the biopharmaceutical industry make him the perfect fit for PhotonPharma as we advance the clinical development of our cancer therapy platform, Innocell™," said Terry Opgenorth, Chairman of the Board at PhotonPharma.

"His track record of commercial success and ability to lead teams through critical product phases will be key as we work to bring this groundbreaking treatment to patients," Opgenorth added.

"I'm honored to lead PhotonPharma at such a pivotal time in the company's journey. PhotonPharma's differentiated and novel cancer immunotherapy programs show great promise to improve the outcomes for patients with solid tumors. I look forward to working closely with the talented team and with the City of Hope as we prepare to launch our first Phase 1 study," said Derek Brown.

More news about: global pharma | Published by Aishwarya | October - 28 - 2024

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members